Autoimmune Cytopenia as an Early and Initial Presenting Manifestation in Activated PI3 Kinase Delta Syndrome: Case Report and Review

Activated PI3 kinase delta syndrome (APDS) is a combined immunodeficiency characterized by recurrent sinopulmonary infections, increased risk of herpesvirus infections, lymphoproliferation, autoimmunity, and increased risk of lymphoid malignancies. Gain-of-function mutations in PIK3CD and PIK3R1 result in increased phosphoinositide-3-kinase-delta activity which causes hyperactivation of lymphocytes and abnormal development and activation of T and B cells. Cytopenias are the most common autoimmune process occurring in patients with APDS and typically occur as a later manifestation of the disease. Here we present a female patient with an early autoimmune hemolytic anemia, hepatosplenomegaly, and frequent infections presenting in infancy, followed by development of significant lymphadenopathy before her diagnosis with APDS type 1. She had significant improvement in her infectious history with immunoglobulin replacement, and control of autoimmune hemolytic anemia with initiation of sirolimus after her diagnosis with APDS type 1. We utilize this case to review the literature on APDS and present the novel finding of early-onset autoimmune disease in the setting of APDS. Autoimmune cytopenias are seen in many primary immunodeficiencies, and workup of autoimmune cytopenias in young patients should include evaluation for underlying immune disorder.

[1]  A. Durandy,et al.  Increased activation of PI3 kinase-δ predisposes to B cell lymphoma. , 2020, Blood.

[2]  Kelli W. Williams,et al.  Hematopoietic Stem Cell Transplantation for Progressive Combined Immunodeficiency and Lymphoproliferation in Patients With Activated Phosphatidylinositol–3–OH Kinase δ Syndrome Type 1 , 2019, Pediatrics.

[3]  J. Bussel,et al.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia. , 2019, Blood advances.

[4]  J. Cannons,et al.  T and B‐cell signaling in activated PI3K delta syndrome: From immunodeficiency to autoimmunity , 2019, Immunological reviews.

[5]  L. Notarangelo,et al.  Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4+ T cells. , 2019, The Journal of allergy and clinical immunology.

[6]  F. Aghamahdi,et al.  Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review , 2019, Clinical Reviews in Allergy & Immunology.

[7]  S. Rosenzweig,et al.  PI3K pathway defects leading to immunodeficiency and immune dysregulation , 2019, The Journal of allergy and clinical immunology.

[8]  S. Tangye,et al.  Immune Dysregulation and Disease Pathogenesis due to Activating Mutations in PIK3CD—the Goldilocks’ Effect , 2019, Journal of Clinical Immunology.

[9]  L. Notarangelo Hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Who, when, and how? , 2019, The Journal of allergy and clinical immunology.

[10]  S. Choo,et al.  Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity , 2019, The Journal of allergy and clinical immunology.

[11]  A. Cant,et al.  The Treatment of Activated PI3Kδ Syndrome , 2018, Front. Immunol..

[12]  G. Uzel,et al.  Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8+ T Cell Survival, Differentiation, and Function , 2018, Front. Immunol..

[13]  J. Orange,et al.  Use of Genetic Testing for Primary Immunodeficiency Patients , 2018, Journal of Clinical Immunology.

[14]  A. Fischer,et al.  Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry , 2018, Front. Immunol..

[15]  B. Sloth,et al.  Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib. , 2017, Blood.

[16]  Lewis C. Cantley,et al.  The PI3K Pathway in Human Disease , 2017, Cell.

[17]  F. Alt,et al.  Phosphatidylinositol 3-Kinase (PI3K) δ blockade increases genomic instability in B cells , 2017, Nature.

[18]  Bodo Grimbacher,et al.  Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study , 2017, The Journal of allergy and clinical immunology.

[19]  C. Cunningham-Rundles,et al.  Autoimmune Cytopenias and Associated Conditions in CVID: a Report From the USIDNET Registry , 2017, Journal of Clinical Immunology.

[20]  K. Okkenhaug,et al.  PI3Kδ and primary immunodeficiencies , 2016, Nature Reviews Immunology.

[21]  T. Molina,et al.  Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study. , 2016, The Journal of allergy and clinical immunology.

[22]  B. Lambrecht,et al.  Genes associated with common variable immunodeficiency: one diagnosis to rule them all? , 2016, Journal of Medical Genetics.

[23]  B. Fevang,et al.  Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency , 2016, Clinical and experimental immunology.

[24]  R. Naik Warm autoimmune hemolytic anemia. , 2015, Hematology/oncology clinics of North America.

[25]  Roger L. Williams,et al.  Synergy in activating class I PI3Ks. , 2015, Trends in biochemical sciences.

[26]  J. Hughes,et al.  Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K , 2014, The Journal of experimental medicine.

[27]  J. B. Oliveira,et al.  Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency , 2013, Nature Immunology.

[28]  Nada Jabado,et al.  Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage , 2013, Science.

[29]  R. Abraham,et al.  Autoimmune Cytopenias In Common Variable Immunodeficiency , 2012, Front. Immun..

[30]  Drew Provan,et al.  International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.